PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8564708

Distribution of immunoreactive 2',5'-oligoadenylate synthetase in mouse digestive tract.

M Asada-Kubota·T Ueda·M Shimada·K Takeda·Y Sokawa
View original source ↗Export metadata ↓

Abstract

2',5'-Oligoadenylate synthetase (2-5OAS), an enzyme induced by interferon (IFN), has also been found in various "normal" animals that had not been treated with IFN. The distribution of this enzyme in the digestive tracts of normal healthy mice was studied by western blotting and by an immunohistochemical method using a specific monoclonal antibody. On western blotting, the antibody to 42 kD 2-5OA synthetase reacted with extracts from the stomach and intestines (small and large intestine), but not with extracts from the esophagus. Immunohistochemically, the 42 kD 2-5OAS was localized on the following cells: surface mucous and parietal cells of fundic glands in the stomach; surface epithelial cells in the intestines; and some enteric nervous cells in the esophagus, stomach, and intestines. Treatment with IFN- alpha/beta did not essentially change the distribution of the enzyme in the tissues, although a small amount of the enzyme was detected in the esophagus by western blotting. Expression of the 42 kD 2-5OAS in the digestive tract may be responsible for the prevention of viral infections.

Explore related subjects

2',5'-Oligoadenylate SynthetaseAnimalsBlotting, WesternDigestive SystemEnzyme InductionEpitheliumEsophagusFemaleGastric MucosaImmunohistochemistryInterferon Type IIntestinal MucosaMiceMice, Inbred ICRMolecular WeightReference ValuesSpleenJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Asada-Kubota, T Ueda, M Shimada, K Takeda, Y Sokawa. 1995. Distribution of immunoreactive 2',5'-oligoadenylate synthetase in mouse digestive tract.. https://doi.org/10.1089/jir.1995.15.863

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein.

Among the many host genes induced by virus infection and interferon, the eIF2alpha protein kinase PKR and the 2'-5' oligoadenylate synthetase (OAS) are both activated by double-stranded RNA (dsRNA) produced in virus-infected cells. Furthermore, each is a critical component that independently acts to inhibit virus replication and thereby contributes to the establishment of an antiviral state. As part of their tactics to foil host defense mechanisms, some viruses prevent the induction of interferon-responsive genes at the level of transcription. Other viruses, such as herpes simplex virus type 1 (HSV-1), can additionally replicate in interferon-treated cells and must also evade the actions of host defense proteins such as PKR and OAS that have been previously synthesized and merely await detection of an activating signal. Whereas HSV-1 gene products gamma(1)34.5 and Us11 are required for viral replication in interferon-treated cells and both act in a temporally coordinated manner during infection to counteract PKR, HSV-1 functions that target OAS have not been described. Here, we demonstrate that HSV-1 infection inhibits 2'-5' oligoadenylate synthesis in interferon-stimulated primary human cells. The OAS-inhibiting activity is generated late in the virus' productive life cycle and requires the Us11 gene product. Moreover, we establish that the Us11 protein is sufficient to block OAS activation in extracts from uninfected, interferon-treated cells. Inhibition of OAS specifically requires the Us11 dsRNA-binding domain, suggesting a mechanism that, in part, relies on sequestering available dsRNA produced during infection. Thus, in addition to PKR and its protein activator, PACT, the HSV-1 Us11 gene product is able to counteract the activity of OAS, a third cellular protein critical for host defense.

2',5'-Oligoadenylate Synthetase↗
PubMed2007

Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Interferons (IFNs) are used widely in the treatment of viral infections, tumours and neurological disorders. The aim of this study was to evaluate the endogenous expressions of various IFN-induced compounds [specifically: neopterin (NPT), beta2microglobulin (beta2mg) and 2-5 oligoadenylate synthetase (2-5 OAS)] in patients with various chronic diseases requiring treatment with IFN type I. The results showed that patients with such chronic diseases as hepatitis C virus-associated type II mixed cryoglobulinaemia (MC), chronic hepatitis C (CHC) and relapsing-remitting multiple sclerosis (RRMS) are characterized by different activations of the IFN system. Furthermore, the interindividual variability in baseline levels of IFN-induced biomarkers was higher in patients with chronic diseases than in healthy individuals. When levels of the above biomarkers were measured 24 h after the first injection of IFN in patients with CHC or RRMS, significant increases in expression levels of IFN-induced compounds were recorded but, again, there is a broad range of variability in the degree of increase. Further, a significant inverse correlation between baseline levels of NPT, beta2mg and 2-5 OAS activity and their relative increases after IFN administration was found in patients with CHC or RRMS. Together, the results are consistent with the observation that there is considerable interindividual heterogeneity in the clinical response to IFNs, which suggests that host factors other than disease markers must be taken into account in order to manage and optimize the IFN therapy.

2',5'-Oligoadenylate Synthetase↗
PubMed2006

The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.

Interferon (IFN)-alpha, -beta and -gamma have been shown to be only marginally effective against severe acute respiratory syndrome coronavirus (SARS-CoV) replication in Vero cell lines. We investigated the combination of type I IFNs (IFN-alpha or -beta) and IFN-gamma for antiviral activity and found that such combinations synergistically inhibited SARS-CoV replication in Vero cells, using yield reduction assay and the isobologram and combination index methods of Chou and Talalay for evaluation. The highly synergistic anti-SARS-CoV action of type I IFNs and IFN-gamma parallels the marked increase in 2'-5'-oligoadenylate synthetase and p56 mRNAs following exposure in Vero cells to either IFN-alpha or -beta and IFN-gamma compared with the transcriptional levels obtained after stimulation with either IFN alone. These results demonstrate that SARS-CoV, although only moderately sensitive to the antiviral action of the individual types of IFN, is highly sensitive to a combination of type I and II IFNs, which suggests that such combinations may have potential in the treatment of SARS-CoV infections.

2',5'-Oligoadenylate Synthetase↗